Free Trial

Vicarious Surgical (NYSE:RBOT) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Vicarious Surgical logo with Medical background

Vicarious Surgical (NYSE:RBOT - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($2.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.61) by $0.03, Zacks reports.

Vicarious Surgical Trading Up 0.8%

RBOT stock traded up $0.07 during mid-day trading on Monday, hitting $8.69. The stock had a trading volume of 29,400 shares, compared to its average volume of 33,914. Vicarious Surgical has a 1-year low of $4.27 and a 1-year high of $19.00. The company has a fifty day moving average of $7.24 and a 200 day moving average of $10.70. The stock has a market capitalization of $51.54 million, a price-to-earnings ratio of -0.84 and a beta of 1.46.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reduced their price objective on Vicarious Surgical from $10.50 to $8.50 and set a "neutral" rating for the company in a research note on Tuesday, March 18th.

Get Our Latest Stock Analysis on Vicarious Surgical

About Vicarious Surgical

(Get Free Report)

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Featured Articles

Earnings History for Vicarious Surgical (NYSE:RBOT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vicarious Surgical Right Now?

Before you consider Vicarious Surgical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vicarious Surgical wasn't on the list.

While Vicarious Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 AI ETFs for Steady Gains in 2025 (Without the Wild Volatility)
Goldman Sachs Warns of 20% Market Drop—Are They Right?
Top 3 Insider Stock Buys in April—Are They Still Good in May?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines